A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

NCT02217007 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Funding stopped, company closed

Conditions

Tourette Syndrome

Interventions

DRUG: SNC-102 sustained release tablet

Sponsor

Synchroneuron Inc.